Peter A. Forsberg

Oncology

1721 E 19th Ave Ste 100
Denver, CO 80218

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma.

Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma.

Journal: Blood advances

Published: October 22, 2025

Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma.

Dexamethasone prophylaxis for excessive lymphocyte expansion after cilta-cel in multiple myeloma.

Journal: Blood advances

Published: October 22, 2025

FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.

FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.

Journal: Nature medicine

Published: October 03, 2025

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

Journal: Blood cancer journal

Published: September 29, 2025

Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.

Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response.

Journal: American journal of hematology

Published: July 30, 2025

Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium.

Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy Consortium.

Journal: Transplantation and cellular therapy

Published: May 05, 2025

Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.

Safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy for the treatment of plasma cell leukemia.

Journal: Blood advances

Published: April 25, 2025

Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.

Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 07, 2025

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 18, 2025

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma.

Journal: Blood advances

Published: February 05, 2025

Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium.

Journal: Blood cancer discovery

Published: December 24, 2024

Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.

Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.

Journal: Journal of hematology & oncology

Published: March 26, 2024

Showing 1-12 of 35

Last Updated: 09/26/2026